Novo Nordisk Reveals Tresiba US Pricing Premium To Levemir
This article was originally published in Scrip
Executive Summary
Novo Nordisk AS says its ultra-long-acting insulin Tresiba will be launched in the US at a 10% premium to the Danish company's currently marketed Levemir (insulin detemir) and made available first to specialists and pharmacies there in the fourth quarter, with full commercial launch slated for the first quarter of 2016.